Latest news with #BK
Scotsman
4 hours ago
- Entertainment
- Scotsman
Burger King UK unveils new 'Barbie rescue' bundle for summer
Burger King® UK is firing up a BBQ rescue mission with the flame-grilled feast Burger King UK has launched a brand new bundle to save Brits from disastrous BBQ blunders this summer, offering customers a choice of two BK favourites, the flame-grilled Whopper, the juicy Chicken Royale or a satisfying Bacon Double Cheeseburger, complemented by two kids' mains, golden Fries and fiery Chilli Cheese Bites. The bundle comes new research reveals over 30% of Brits admit that home-cooked BBQs rarely live up to the hype. The bundle is perfect for families and is the ultimate feast for when a BBQ goes wrong or the weather ruins the day. Customers can even DM a pic of their BBQ blunder to @burgerkinguk to use the UK's first 'Barbe-res-cue' hotline…. perfect for those who find themselves in a charred chicken or a limp lettuce situation. Those who submit a picture can be in luck to bag themselves a FREE Whopper® or iconic Chicken Royale via the Burger King® UK app*.
Yahoo
7 hours ago
- Health
- Yahoo
Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection
Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability concerns were observed Supports progression into Phase III development with the potential to transform the treatment landscape for kidney transplant patients with BK polyomavirus infection Further results from the trial to be presented at the World Transplant Congress in San Francisco, 2-6 August Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx'), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus ('BKPyV')-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients ('KTR'). The randomized, double-blind, placebo-controlled SAFE KIDNEY II trial enrolled 95 patients across 22 U.S. sites (NCT05769582) to evaluate the clinical effectiveness of potravitug in reducing BKPyV infection in blood and kidney tissue. While the primary endpoint – undetectable BKPyV DNAemia in blood – was not met with statistical significance, the treatment group demonstrated significantly higher viral response (defined as ≥1 log₁₀ reduction in BK viral load) with resolution of biopsy-proven BK polyomavirus nephropathy ('BKPyVAN') by week 20. This histological improvement in BKPyVAN indicated resolution of the underlying disease, decreasing from 51.2% at baseline to 31.6% at week 20 in the treatment group, while no change was observed in the placebo group (23.8% vs 24.4%). The trial also demonstrated that potravitug dosed at 1,000mg achieved a greater reduction in BKPyV DNAemia compared to placebo, with 61.0% of patients receiving potravitug showing a ≥1-log₁₀ reduction from baseline or achieving levels below the lower limit of quantification ('LLOQ') at week 20, compared to 40.5% in the placebo group. Potravitug had a favorable safety profile with no treatment-related serious adverse events or withdrawals due to adverse events. "These promising results mark a significant milestone in our mission to develop the first approved treatment for BKPyV infection in kidney transplant recipients," said Erik van den Berg, CEO of MTx. "The resolution of BKPyV infection and its associated damage, positions potravitug as a potentially transformative treatment for kidney transplant patients. This was the first placebo-controlled study with prospective kidney biopsies, evaluating the correlation between BKPyV viral load in blood and viral presence in kidney tissue. Based on the data we see a clear path to market for this serious condition, which affects thousands of transplant patients annually." Nadiesda Costa, MD, MPH, Associate Professor of Medicine, Georgetown University School of Medicine, and Principal Investigator, added: "The results from this trial are exciting and represent a potential breakthrough in the treatment of BKPyV infection in kidney transplant patients, especially given that there are no specific antiviral therapies for BK viremia available. The data showed strong results in demonstrating pathologic improvement in BKPyVAN which, combined with a supportive safety profile, is highly encouraging for future clinical studies." Based on these exciting results, MTx plans to advance potravitug into Phase III development and engage with regulatory authorities to discuss trial design later this year. MTx received fast-track designation for potravitug from the FDA in May 2023 in recognition of the high unmet medical need. Further results from the Phase II clinical trial will be presented at the World Transplant Congress in San Francisco taking place 2-6 August 2025, details below. Session: LOA04 - Late Breaking Studies in Transplant Infectious Diseases Title: Potravitug for the Treatment of BK Polyomavirus Infection in Kidney Transplant Recipients: A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Presenter/Authors: N. Costa*, D. Dadhania, W. Asch, A. Haririan, C. Kew, M. Pavlakis, K. Fowler, J. Beck, D. Wojciechowski Date & Time: 4 August, 2025, 4:30 PM - 5:45 PM -Ends- Contacts Memo Therapeutics AG info@ ICR Healthcare Amber Fennell, Ashley Tapp memotx@ +44 (0)20 3709 5700 About Memo Therapeutics AGMemo Therapeutics AG ('MTx') is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company's lead program, potravitug, targeting BKPyV infection in kidney transplant recipients is planned to start Phase III clinical development in 2026. BKPyV infections decrease kidney functionality and longevity and reduce patient survival. Potravitug has the potential to become a first-in-class BKPyV disease-modifying therapy for kidney transplant patients with a market potential of up to $2bn p.a.. Alongside potravitug, MTx is focused on discovering novel antibody-target-pairs in oncology. Underpinning MTx's core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at and on LinkedIn. About BK polyomavirus in kidney transplant recipientsMore than 100,000 kidney transplants are conducted worldwide every year. BKPyV can become reactivated in up to 50% of these patients and up to 70% of patients with BKPyV viremia develop BKPyV nephropathy, which significantly increases the risks of kidney loss and patient in retrieving data Sign in to access your portfolio Error in retrieving data
Business Upturn
12 hours ago
- Health
- Business Upturn
Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection
Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability concerns were observed Supports progression into Phase III development with the potential to transform the treatment landscape for kidney transplant patients with BK polyomavirus infection Further results from the trial to be presented at the World Transplant Congress in San Francisco, 2-6 August Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ('MTx'), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus ('BKPyV')-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients ('KTR'). The randomized, double-blind, placebo-controlled SAFE KIDNEY II trial enrolled 95 patients across 22 U.S. sites (NCT05769582) to evaluate the clinical effectiveness of potravitug in reducing BKPyV infection in blood and kidney tissue. While the primary endpoint – undetectable BKPyV DNAemia in blood – was not met with statistical significance, the treatment group demonstrated significantly higher viral response (defined as ≥1 log₁₀ reduction in BK viral load) with resolution of biopsy-proven BK polyomavirus nephropathy ('BKPyVAN') by week 20. This histological improvement in BKPyVAN indicated resolution of the underlying disease, decreasing from 51.2% at baseline to 31.6% at week 20 in the treatment group, while no change was observed in the placebo group (23.8% vs 24.4%). The trial also demonstrated that potravitug dosed at 1,000mg achieved a greater reduction in BKPyV DNAemia compared to placebo, with 61.0% of patients receiving potravitug showing a ≥1-log₁₀ reduction from baseline or achieving levels below the lower limit of quantification ('LLOQ') at week 20, compared to 40.5% in the placebo group. Potravitug had a favorable safety profile with no treatment-related serious adverse events or withdrawals due to adverse events. 'These promising results mark a significant milestone in our mission to develop the first approved treatment for BKPyV infection in kidney transplant recipients,' said Erik van den Berg, CEO of MTx. 'The resolution of BKPyV infection and its associated damage, positions potravitug as a potentially transformative treatment for kidney transplant patients. This was the first placebo-controlled study with prospective kidney biopsies, evaluating the correlation between BKPyV viral load in blood and viral presence in kidney tissue. Based on the data we see a clear path to market for this serious condition, which affects thousands of transplant patients annually.' Nadiesda Costa, MD, MPH, Associate Professor of Medicine, Georgetown University School of Medicine, and Principal Investigator, added: 'The results from this trial are exciting and represent a potential breakthrough in the treatment of BKPyV infection in kidney transplant patients, especially given that there are no specific antiviral therapies for BK viremia available. The data showed strong results in demonstrating pathologic improvement in BKPyVAN which, combined with a supportive safety profile, is highly encouraging for future clinical studies.' Based on these exciting results, MTx plans to advance potravitug into Phase III development and engage with regulatory authorities to discuss trial design later this year. MTx received fast-track designation for potravitug from the FDA in May 2023 in recognition of the high unmet medical need. Further results from the Phase II clinical trial will be presented at the World Transplant Congress in San Francisco taking place 2-6 August 2025, details below. Session: LOA04 – Late Breaking Studies in Transplant Infectious Diseases Title: Potravitug for the Treatment of BK Polyomavirus Infection in Kidney Transplant Recipients: A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Presenter/Authors: N. Costa*, D. Dadhania, W. Asch, A. Haririan, C. Kew, M. Pavlakis, K. Fowler, J. Beck, D. Wojciechowski Date & Time: 4 August, 2025, 4:30 PM – 5:45 PM -Ends- About Memo Therapeutics AG Memo Therapeutics AG ('MTx') is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company's lead program, potravitug, targeting BKPyV infection in kidney transplant recipients is planned to start Phase III clinical development in 2026. BKPyV infections decrease kidney functionality and longevity and reduce patient survival. Potravitug has the potential to become a first-in-class BKPyV disease-modifying therapy for kidney transplant patients with a market potential of up to $2bn p.a.. Alongside potravitug, MTx is focused on discovering novel antibody-target-pairs in oncology. Underpinning MTx's core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at and on LinkedIn. About BK polyomavirus in kidney transplant recipients More than 100,000 kidney transplants are conducted worldwide every year. BKPyV can become reactivated in up to 50% of these patients and up to 70% of patients with BKPyV viremia develop BKPyV nephropathy, which significantly increases the risks of kidney loss and patient death. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
13 hours ago
- Health
- Yahoo
Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection
Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability concerns were observed Supports progression into Phase III development with the potential to transform the treatment landscape for kidney transplant patients with BK polyomavirus infection Further results from the trial to be presented at the World Transplant Congress in San Francisco, 2-6 August Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx'), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus ('BKPyV')-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients ('KTR'). The randomized, double-blind, placebo-controlled SAFE KIDNEY II trial enrolled 95 patients across 22 U.S. sites (NCT05769582) to evaluate the clinical effectiveness of potravitug in reducing BKPyV infection in blood and kidney tissue. While the primary endpoint – undetectable BKPyV DNAemia in blood – was not met with statistical significance, the treatment group demonstrated significantly higher viral response (defined as ≥1 log₁₀ reduction in BK viral load) with resolution of biopsy-proven BK polyomavirus nephropathy ('BKPyVAN') by week 20. This histological improvement in BKPyVAN indicated resolution of the underlying disease, decreasing from 51.2% at baseline to 31.6% at week 20 in the treatment group, while no change was observed in the placebo group (23.8% vs 24.4%). The trial also demonstrated that potravitug dosed at 1,000mg achieved a greater reduction in BKPyV DNAemia compared to placebo, with 61.0% of patients receiving potravitug showing a ≥1-log₁₀ reduction from baseline or achieving levels below the lower limit of quantification ('LLOQ') at week 20, compared to 40.5% in the placebo group. Potravitug had a favorable safety profile with no treatment-related serious adverse events or withdrawals due to adverse events. "These promising results mark a significant milestone in our mission to develop the first approved treatment for BKPyV infection in kidney transplant recipients," said Erik van den Berg, CEO of MTx. "The resolution of BKPyV infection and its associated damage, positions potravitug as a potentially transformative treatment for kidney transplant patients. This was the first placebo-controlled study with prospective kidney biopsies, evaluating the correlation between BKPyV viral load in blood and viral presence in kidney tissue. Based on the data we see a clear path to market for this serious condition, which affects thousands of transplant patients annually." Nadiesda Costa, MD, MPH, Associate Professor of Medicine, Georgetown University School of Medicine, and Principal Investigator, added: "The results from this trial are exciting and represent a potential breakthrough in the treatment of BKPyV infection in kidney transplant patients, especially given that there are no specific antiviral therapies for BK viremia available. The data showed strong results in demonstrating pathologic improvement in BKPyVAN which, combined with a supportive safety profile, is highly encouraging for future clinical studies." Based on these exciting results, MTx plans to advance potravitug into Phase III development and engage with regulatory authorities to discuss trial design later this year. MTx received fast-track designation for potravitug from the FDA in May 2023 in recognition of the high unmet medical need. Further results from the Phase II clinical trial will be presented at the World Transplant Congress in San Francisco taking place 2-6 August 2025, details below. Session: LOA04 - Late Breaking Studies in Transplant Infectious Diseases Title: Potravitug for the Treatment of BK Polyomavirus Infection in Kidney Transplant Recipients: A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Presenter/Authors: N. Costa*, D. Dadhania, W. Asch, A. Haririan, C. Kew, M. Pavlakis, K. Fowler, J. Beck, D. Wojciechowski Date & Time: 4 August, 2025, 4:30 PM - 5:45 PM -Ends- Contacts Memo Therapeutics AG info@ ICR Healthcare Amber Fennell, Ashley Tapp memotx@ +44 (0)20 3709 5700 About Memo Therapeutics AGMemo Therapeutics AG ('MTx') is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company's lead program, potravitug, targeting BKPyV infection in kidney transplant recipients is planned to start Phase III clinical development in 2026. BKPyV infections decrease kidney functionality and longevity and reduce patient survival. Potravitug has the potential to become a first-in-class BKPyV disease-modifying therapy for kidney transplant patients with a market potential of up to $2bn p.a.. Alongside potravitug, MTx is focused on discovering novel antibody-target-pairs in oncology. Underpinning MTx's core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at and on LinkedIn. About BK polyomavirus in kidney transplant recipientsMore than 100,000 kidney transplants are conducted worldwide every year. BKPyV can become reactivated in up to 50% of these patients and up to 70% of patients with BKPyV viremia develop BKPyV nephropathy, which significantly increases the risks of kidney loss and patient while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Daily Mirror
18-07-2025
- Health
- Daily Mirror
'I almost died twice from booze and takeaways, then I lost 6st without jabs'
A man from East London has revealed how his unhealthy lifestyle almost killed him not once, but twice, before he managed to turn things around without weight loss jabs Binge drinking, living on takeaways and enjoying a sedentary lifestyle were the norm for Michael Epstein his 20s and early 30s. But his unhealthy lifestyle left him weighing 18 stone and facing death not once, but twice. Now aged 46 Michael, from Ilford, London, is thankful to be alive after two kidney transplants and then nearly dying from Covid. After years of neglect, the entrepreneur was diagnosed with kidney failure in 2008 and endured dialysis for five gruelling years. 'It was totally my fault as I treated my body terribly,' Michael tells The Mirror. 'I was completely careless with my health. 'I never exercised, I ate all the wrong things and I was always out drinking,' he adds. 'I just thought I was invincible. I didn't think anything would catch up with me. Then it all did, at once. I was exhausted all the time, bloated, and just felt awful. Eventually I was told my kidneys were shutting down and I'd need to start dialysis immediately." In 2014, he was given a lifeline - a new kidney from an 18-year-old male donor from Newcastle, who had died suddenly. 'The hospital called me out of the blue and said 'you've got to get here within the hour'. It was a relief for me but heartbreak for someone else's family. I've always felt such deep gratitude for that gift.' But just as Michael was starting to rebuild his life, he contracted the BK virus - a dangerous infection that can sometimes strike transplant patients and cause kidney failure. Disaster struck again in January 2021 when, at the height of the Covid-19 pandemic, Michael caught the virus and his oxygen levels fell to 30 per cent. He was put into an induced coma for three months and when he finally woke up in April 2021, he was covered in hair and barely able to walk. 'I looked like Tom Hanks in Castaway,' he laughs. 'I had a massive beard, I couldn't move, and I had to learn to walk again. My mum later told me she was scared to answer the phone because she thought every call was going to be the hospital saying I'd died.' Michael was back on dialysis - four hours a day, three days a week - and his mental health was suffering badly. After receiving a second kidney transplant in June 2023 from a 35-year-old woman from South London, Michael felt like he had been 'given one final chance'. 'I felt completely broken,' he said. 'I was reading books just to stay sane during dialysis. I knew if I didn't find some kind of purpose, I'd spiral. I thought I've eaten badly for most of my life. Maybe now's the time to fix that and help others do the same.' His near death experiences drove him to launch Datekin - a healthy snack that was inspired by Sukkari dates - caramel-tasting dates from Saudi Arabia, known for their high fibre, natural sugar and antioxidant-rich benefits. 'This brand was born from pain - but also purpose,' Michael explains. 'I've been given a second, no - a third - shot at life. I want to make it count. I honestly never expected Datekin to take off so quickly. We started trialling it on the London Underground and people loved it. I think people really want better snack options.' After losing six stone by cutting out takeaways, alcohol and exercising, Michael is now looking forward to marrying his fiancée, Kat Conway, next spring. Kat says: "Mike has been through so much with his health over the years and has kept such a positive and proactive outlook. We'll be forever grateful to the two donors, and their families, without whom our life would be very different. For Mike to be in the place he is in today with his health and work is truly inspiring Michael adds: 'I used to treat my body like a bin. Now I think of it like a garden - I'm trying to nourish it. I want Datekin to inspire people to eat well, live better, and understand it's never too late to change.'
